Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab

journals.sagepub.com/home/taw 133 Posterior reversible encephalopathy syndrome (PRES) associates headaches, encephalopathy, seizures and visual disturbances with typical magnetic resonance imaging (MRI) findings. PRES is reversible and benign in most of cases, although sequels may exist, and fatal outcomes have been described in up to 19% [Alhilali et al. 2014; Fugate and Rabinstein, 2015]. Some PRES were associated to targeted therapies [Fugate and Rabinstein, 2015], including cetuximab [KamiyaMatsuoka et al. 2016; Palma et al. 2011], a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Panitumumab is a fully human recombinant monoclonal antibody with a high binding affinity to human EGFR. Here we report and discuss the occurrence of a PRES in a patient presenting with colitis and treated with panitumumab. Patient consent was obtained and patient confidentiality was maintained.

[1]  Kazuhiro Yoshida,et al.  Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer , 2016, Cancer Chemotherapy and Pharmacology.

[2]  S. Tummala,et al.  Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study , 2016, Journal of Neuro-Oncology.

[3]  C. Xie,et al.  Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review. , 2016, Oncology letters.

[4]  A. Rabinstein,et al.  Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions , 2015, The Lancet Neurology.

[5]  A. Ganti,et al.  Renal Toxicities of Targeted Therapies , 2015, Targeted Oncology.

[6]  S. Fakhran,et al.  A multi-disciplinary model of risk factors for fatal outcome in posterior reversible encephalopathy syndrome , 2014, Journal of the Neurological Sciences.

[7]  P. Striano,et al.  Posterior reversible encephalopathy syndrome: the endothelial hypotheses. , 2014, Medical hypotheses.

[8]  B. Escudier,et al.  Reversible posterior leukoencephalopathy syndrome induced by axitinib. , 2014, Clinical genitourinary cancer.

[9]  R. Russell,et al.  A case of posterior reversible encephalopathy syndrome in a child with Crohn's disease treated with Infliximab. , 2011, Journal of Crohn's & colitis.

[10]  O. Mir,et al.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents , 2011, Targeted Oncology.

[11]  M. Pastor,et al.  Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab. , 2011, The neurologist.

[12]  S. K. Mukherji,et al.  Panitumumab (Vectibix) , 2011, American Journal of Neuroradiology.

[13]  H. Per,et al.  Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature , 2010, Neurological Sciences.

[14]  D. Schiff,et al.  Reversible posterior leukoencephalopathy syndrome in cancer , 2008, Current oncology reports.

[15]  J. Boardman,et al.  Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. , 2006, AJNR. American journal of neuroradiology.

[16]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[17]  T. Ashida,et al.  Reversible Posterior Leukoencephalopathy Syndrome Associated with Treatment for Acute Exacerbation of Ulcerative Colitis. , 2016, Internal medicine.